Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Parecoxib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 11/20 | 1.00 |
| ▸ | NR4A2 | P43354 | 1/20 | 1.00 |
| ▸ | MT-CO2 | P00403 | 3/20 | 0.72 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | CA3 | P07451 | 1/20 | 0.61 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.61 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.61 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.61 |
| ▸ | CA4 | P22748 | 1/20 | 0.61 |
| ▸ | CA6 | P23280 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | PDE4A | P27815 | 1/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Parecoxib SCHEMBL29561416 | 1.00 | PTGS2 (1.00) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| SCHEMBL28646416 | 1.00 | PTGS2 (1.00) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| Parecoxib SCHEMBL28381051 | 0.99 | PTGS2 (0.98) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| Parecoxib SCHEMBL117193 | 0.99 | PTGS2 (0.98) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| Parecoxib SCHEMBL5709079 | 0.99 | PTGS2 (0.98) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| Parecoxib SCHEMBL28339255 | 0.98 | PTGS2 (0.96) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| Parecoxib SCHEMBL28086681 | 0.95 | PTGS2 (0.90) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| SCHEMBL12546410 | 0.92 | PTGS2 (0.85) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| SCHEMBL13772645 | 0.92 | PTGS2 (0.85) | PTGS2NR4A2MT-CO2PTGS1CA12 | |
| SCHEMBL5071003 | 0.91 | PTGS2 (0.84) | PTGS2NR4A2MT-CO2PTGS1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 23976 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-12605432-B2 | Combinations for antigen based therapy | DIAMYD MEDICAL AB (SE) | 2026-04-21 | — | — | US | claimed |
| US-12600696-B2 | Aromatic compounds | Xeniopro GmbH (DE) | 2026-04-14 | — | — | US | claimed |
| US-20260069532-A1 | METHOD FOR MORSELIZING AND/OR TARGETING PHARMACEUTICALLY ACTIVE PRINCIPLES TO SYNOVIAL TISSUE | MEDINCELL S.A. (FR) | 2026-03-12 | — | — | US | claimed |
| US-12558309-B2 | Method for morselizing and/or targeting pharmaceutically active principles to synovial tissue | MEDINCELL S.A. (FR) | 2026-02-24 | — | — | US | claimed |
| US-12545750-B2 | Method for the diimide hydrogenation of emulsified unsaturated polymers | PARKER DANE K (US) | 2026-02-10 | — | — | US | claimed |
| US-20260027178-A1 | Treatment Of Parkinson's Disease With SIM BHLH Transcription Factor 2 (SIM2) Agonists | REGENERON PHARMA (US) | 2026-01-29 | — | — | US | claimed |
| US-20260000741-A1 | METHOD OF AMELIORATING A PRO-INFLAMMATORY IMMUNOPHENOTYPE IN FARBER DISEASE SUBJECTS BY REPEATED ADMINISTRATION OF A RECOMBINANT HUMAN ACID CERAMIDASE | ACERAGEN INC (US) | 2026-01-01 | — | — | US | claimed |
| US-12502383-B2 | Pharmaceutical composition of cyclooxygenase-2 inhibitors | THEMIS MEDICARE LIMITED (IN) | 2025-12-23 | — | — | US | claimed |
| WO-2001015687-A1 | METHOD FOR TREATING OR PREVENTING CHRONIC PROSTATITIS OR CHRONIC PELVIC PAIN SYNDROME | MERCK & CO., INC. (US) | 2001-03-08 | — | — | WO | claimed |
| WO-2001008682-A2 | USE OF FLUPIRTINE FOR ALLEVIATING PAIN CAUSED BY DEGENERATIVE JOINT DISEASES IN DOGS AND CATS | AWD.PHARMA GMBH & CO. KG (DE) | 2001-02-08 | — | — | WO | claimed |
| WO-2001000229-A1 | COMBINATION OF TUMORS NECROCIS FACTOR (TNF) ANTAGONISTS AND COX-2 INHIBITORS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2001-01-04 | — | — | WO | claimed |
| WO-2000051685-A1 | COMPOSITION COMPRISING A TRAMADOL MATERIAL AND A SELECTIVE COX-2 INHIBITOR DRUG | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-09-08 | — | — | WO | claimed |
| JP-2000509029-A | — | — | 2000-07-18 | — | — | JP | claimed |
| WO-2000038730-A2 | USE OF A CYCLOOXYGENASE-2 INHIBITOR AND ONE OR MORE ANTINEOPLASTIC AGENTS FOR COMBINATION THERAPY IN NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | claimed |
| WO-2000038786-A2 | USE OF CYCLOOXYGENASE 2 INHIBITOR AND AN INTEGRIN ANTAGONIST AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | claimed |
| WO-2000037107-A2 | USE OF CYCLOOXYGENASE-2 INHIBITOR, A MATRIX METALLAPROTEINASE INHIBITOR, AN ANTINEOPLASTIC AGENT AND OPTIONALLY RADIATION AS A COMBINATION TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-06-29 | — | — | WO | claimed |
| EP-0892791-A1 | SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES AS PRODRUGS OF COX-2 INHIBITORS | G.D. SEARLE & CO. (US) | 1999-01-27 | — | — | EP | claimed |
| WO-1997038986-A1 | SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES AS PRODRUGS OF COX-2 INHIBITORS | G.D. SEARLE & CO. (US) | 1997-10-23 | — | — | WO | claimed |